通过目标导向亚组识别从多组学研究得出共识性脓毒症聚类
该研究提出目标导向亚组识别(GD-SI)框架,整合来自43家医院1327名受试者的纵向多组学数据(转录组、蛋白质组、代谢组、表型组),将亚组发现直接锚定于治疗效应优化。该策略实现跨组学高度一致性,并能推广至国际重症监护数据库预测差异治疗反应。按GD-SI衍生的限制性与开放性液体复苏获益评分分层的患者表现出显著生存差异,乌司他丁免疫调节也观察到类似优势。在MIMIC-IV和ZiGongDB中的外部验证证实了预后可推广性。
要点
- GD-SI框架整合1327名受试者、43家医院的纵向多组学数据,将亚组发现直接锚定于治疗效应优化。
- 按GD-SI衍生的限制性与开放性液体复苏获益评分分层的患者表现出显著生存差异。
- 乌司他丁免疫调节也观察到类似的生存优势。
- 外部验证在MIMIC-IV和ZiGongDB中证实预后可推广性。
- 该框架实现跨组学高度一致性,并推广至国际重症监护数据库预测差异治疗反应。
适用人群与场景
- 脓毒症患者:因宿主对感染反应失调导致危及生命的器官功能障碍综合征。
- 研究纳入来自43家医院的1327名受试者。
研究设计与关键结果
- 研究类型为多组学研究,样本量1327名受试者,来自43家医院。
- 干预为GD-SI框架整合纵向多组学数据(转录组、蛋白质组、代谢组、表型组)进行目标导向亚组识别。
- 主要终点结果:按GD-SI衍生的限制性与开放性液体复苏获益评分分层的患者表现出显著生存差异。
- 关键次要终点:乌司他丁免疫调节也观察到类似优势。
- 外部验证在MIMIC-IV和ZiGongDB中证实预后可推广性。
证据类型、等级与局限
- 证据类型:多组学研究(整合纵向多组学数据的观察性研究)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Sepsis, a syndrome of life-threatening organ dysfunction caused by dysregulated host responses to infection, exhibits profound pathobiological heterogeneity, hindering the development of effective therapies. Current subtyping approaches, often reliant on single-omics data or unsupervised clustering, yield poorly reproducible and therapeutically misaligned classifications. Here, we introduce a goal-directed subgroup identification (GD-SI) framework that optimizes patient stratification for differential treatment responses, integrating longitudinal multi-omics data (transcriptomic, proteomic, metabolomic, phenomic) from 1327 subjects across 43 hospitals. While supervised multi-omics integration frameworks (e.g., DIABLO) effectively capture shared biological signals, our approach anchors subgroup discovery directly to treatment-effect optimization. This strategy achieves substantial cross-omic concordance and, crucially, generalizes to predict differential treatment response across international critical care databases. Patients stratified by GD-SI-derived benefit scores for restrictive versus liberal fluid resuscitation exhibited marked survival differences, with similar advantages observed for ulinastatin immunomodulation. External validations in MIMIC-IV and ZiGongDB confirm prognostic generalizability. This framework reconciles biological heterogeneity with clinical actionability, offering a scalable infrastructure for precision trial design and personalized sepsis management. Our findings underscore the translational potential of omics-driven, goal-directed stratification to overcome decades of therapeutic stagnation in critical care.
参考来源
- Zhang Z, Chen L, Shen H, et al. Deriving consensus sepsis clusters via goal-directed subgroup identification in multi-omics study. Nat Commun. 2025. PMID: 41285725. doi:10.1038/s41467-025-65271-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。